November 29, 2016
Chugai Pharmaceutical said on November 28 that it will grant German drug maker Berlin-Chemie Menarini exclusive global rights to develop, manufacture, and commercialize its class I PI3K inhibitor PA799, an investigational treatment for solid tumors. Under the deal, Chugai will...read more